Omeza warned over poor man­u­fac­tur­ing con­di­tions; MiMedx in FDA talks over Ax­iofill re­clas­si­fi­ca­tion

Skin health com­pa­ny Omeza was is­sued an FDA warn­ing let­ter af­ter sev­er­al man­u­fac­tur­ing is­sues were un­cov­ered at its site in Sara­so­ta, FL. Mean­while, MiMedx is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER